

Sun Pharmaceutical Industries, Inc.

Vermont New Product Launch Report

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE	WAC AT INTRODUCTION
57664095088	Mixed Amphetamine ER Capsules 12.5mg 100ct	2/20/2024	\$975.81
57664095188	Mixed Amphetamine ER Capsules 25mg 100ct	2/20/2024	\$975.81
57664095288	Mixed Amphetamine ER Capsules 37.5mg 100ct	2/20/2024	\$975.81
57664095388	Mixed Amphetamine ER Capsules 50mg 100ct	2/20/2024	\$975.81

Key **Used for Full Report Due 30 Days After Initial Notice**

missions Made To AGO.highcostprescriptiondrugs@vermont.gov

MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC	ESTIMATED PATIENTS
<p>As this is a generic pharmaceutical product, Sun does not engage in marketing activities typically attendant to branded products. There are no direct to consumer marketing activities of any kind, and no promotion of the product to physicians or other healthcare providers. Sun contracts with specialty pharmacies and wholesalers.</p> <p>Sun utilized appropriate pricing planning based on current and predicted market conditions. In this instance, utilizing only publically available information Sun determined aligning WAC with other generic companies already in the market would enable it to maximize sales and minimize competitive risk.</p>	N	12,000,000
<p>As this is a generic pharmaceutical product, Sun does not engage in marketing activities typically attendant to branded products. There are no direct to consumer marketing activities of any kind, and no promotion of the product to physicians or other healthcare providers. Sun contracts with specialty pharmacies and wholesalers.</p> <p>Sun utilized appropriate pricing planning based on current and predicted market conditions. In this instance, utilizing only publically available information Sun determined aligning WAC with other generic companies already in the market would enable it to maximize sales and minimize competitive risk.</p>	N	12,000,000
<p>As this is a generic pharmaceutical product, Sun does not engage in marketing activities typically attendant to branded products. There are no direct to consumer marketing activities of any kind, and no promotion of the product to physicians or other healthcare providers. Sun contracts with specialty pharmacies and wholesalers.</p> <p>Sun utilized appropriate pricing planning based on current and predicted market conditions. In this instance, utilizing only publically available information Sun determined aligning WAC with other generic companies already in the market would enable it to maximize sales and minimize competitive risk.</p>	N	12,000,000
<p>As this is a generic pharmaceutical product, Sun does not engage in marketing activities typically attendant to branded products. There are no direct to consumer marketing activities of any kind, and no promotion of the product to physicians or other healthcare providers. Sun contracts with specialty pharmacies and wholesalers.</p> <p>Sun utilized appropriate pricing planning based on current and predicted market conditions. In this instance, utilizing only publically available information Sun determined aligning WAC with other generic companies already in the market would enable it to maximize sales and minimize competitive risk.</p>	N	12,000,000

BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR	ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC	ACQUISITION PRICE COMMENT	GENERAL COMMENTS
N	N			Y/N		
N	N			Y/N		
N	N			Y/N		
N	N			Y/N		